These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

774 related items for PubMed ID: 9533064

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF, Goa KL.
    Drugs; 2003 Sep; 63(24):2769-802. PubMed ID: 14664657
    [Abstract] [Full Text] [Related]

  • 5. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, Kanda M, Tsujio Y, Okada J, Tazawa Y, Watanabe N, Uehara N, Igari J, Oguri T, Kaimori M, Kawamura C, Iinuma Y, Nisawataira T, Tashiro H, Ueno K, Ishigo S, Yasujima M, Kawahara S, Itoh C, Yoshida T, Yamanaka K, Toyoshima S, Katoh J, Kudoh M, Matsushima T, Niki Y, Miyashita N, Funato T, Kaku M, Sato N, Saito Y, Ishii K, Kuwabara M, Hongo T, Negayama K, Kamihira S, Miyazaki Y, Takii M, Ishii M, Nakagawa K, Ono J, Takada T, Murakami N, Taira M, Tamaki I, Matsudou Y, Nakasone I.
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Jun; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
    Ernst ME, Ernst EJ, Klepser ME.
    Am J Health Syst Pharm; 1997 Nov 15; 54(22):2569-84. PubMed ID: 9397218
    [Abstract] [Full Text] [Related]

  • 10. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK.
    Antimicrob Agents Chemother; 2003 Oct 15; 47(10):3260-9. PubMed ID: 14506039
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H, Hayakawa I, Akimoto T.
    Yakushigaku Zasshi; 2003 Oct 15; 38(2):161-79. PubMed ID: 15143768
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN, Pfaller MA.
    Clin Infect Dis; 2000 Aug 15; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
    Hurst M, Lamb HM, Scott LJ, Figgitt DP.
    Drugs; 2002 Aug 15; 62(14):2127-67. PubMed ID: 12269858
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M, Ishida K, Irifune K, Mizukane R, Takemura H, Yoshida R, Tanaka H, Usui T, Tomono K, Suyama N.
    Antimicrob Agents Chemother; 1994 Apr 15; 38(4):738-41. PubMed ID: 8031039
    [Abstract] [Full Text] [Related]

  • 16. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
    DeAbate CA, Henry D, Bensch G, Jubran A, Chodosh S, Harper L, Tipping D, Talbot GH.
    Chest; 1998 Jul 15; 114(1):120-30. PubMed ID: 9674458
    [Abstract] [Full Text] [Related]

  • 17. Levofloxacin, a second-generation fluoroquinolone.
    North DS, Fish DN, Redington JJ.
    Pharmacotherapy; 1998 Jul 15; 18(5):915-35. PubMed ID: 9758306
    [Abstract] [Full Text] [Related]

  • 18. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD, Lamb HM.
    Drugs; 1998 Sep 15; 56(3):487-515. PubMed ID: 9777318
    [Abstract] [Full Text] [Related]

  • 19. Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
    Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 1997 Nov 15; 29(3):199-201. PubMed ID: 9401813
    [Abstract] [Full Text] [Related]

  • 20. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2002 Sep 15; 44(1):77-84. PubMed ID: 12376036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.